Survival advantage of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer: experience from a Western tertiary referral center

Mostrar otras versiones (1)

BACKGROUND: Selection criteria and prognostic factors for patients with advanced gastric cancer (AGC) undergoing cytoreductive surgery (CRS) plus hyperthermic intra-operative peritoneal chemotherapy (HIPEC) have not been well defined and the literature data are not homogeneous. The aim of this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosa, Fausto, Galiandro, Federica, Ricci, Riccardo, Di Miceli, Dario, Longo, Fabio, Quero, Giuseppe, Tortorelli, Antonio Pio, Alfieri, Sergio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8208915/
https://www.ncbi.nlm.nih.gov/pubmed/33611693
http://dx.doi.org/10.1007/s00423-021-02137-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8208915/
https://www.ncbi.nlm.nih.gov/pubmed/33611693
http://dx.doi.org/10.1007/s00423-021-02137-5

Ejemplares similares